#812 Infrapubic Foley catheter balloon tamponade for retropubic venous haemorrhage during radical cystoprostatectomy and urethrectomy

#1311 Nano-Ni0 nanocatalysts disrupt redox homeostasis via hydrogen-induced reductive stress and nickel-driven chemodynamic therapy for bladder cancer treatment and immune modulation

#65 BCG response and oncological outcomes in high risk non-muscle invasive bladder cancer following previously treated upper tract urothelial carcinoma: A propensity-matched analysis

#215 META-ANALYTICAL ASSESSMENT ABOUT STANDARD AND EXTENDED PELVIC LYMPH NODE DISSECTION IN TERMS OF POST-OPERATIVE COMPLICATIONS IN PATIENTS UNDER RADICAL CYSTECTOMY

#216 Anemia is associated with inferior outcomes in non-muscle invasive bladder cancer patients receiving Bacillus Calmette-Guérin immunotherapy

#221 Treatment of Muscle Invasive Bladder Cancer in the Elderly: A systematic review and meta-analysis

#295 Enhancing Individual Survival Prediction in Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy Using Machine and Deep Learning AI models

#298 CD163+ Tumor-Associated Macrophages and GATA3 Expression: Promising Markers for Predicting Post-Surgery Progression in Locally Advanced Upper Tract Urothelial Carcinoma

#371 The use patient-derived prostate cancer organoids as a tool to predict response to therapy

#406 The comparison of robotic-assisted and laparoscopic radical nephroureterectomy in non-metastatic upper tract urothelial carcinoma

#411 Effect of statin use on outcomes of non-muscle-invasive bladder cancer: a systematic review and meta-analysis

#1273 Hyperthermia Intravesical Chemotherapy vs. Bacillus Calmette-Guérin instillation and Mitomycin C Perfusion for Non-muscle-invasive Bladder Cancer: A Network Meta-analysis

#362 Comprehensive Bioinformatics Approach for Identifying Lipid-Related Markers in Bladder Cancer Prognosis

#94 Prediction Nomograms of Prognosis in Bladder Urothelial Carcinoma Patients Receiving Radical Cystectomy-A Two-center Retrospective Research

#131 Preclinical assessment of anti-PVR antibody-drug conjugate in bladder urothelial carcinoma